Venus cept (VERO)
Search documents
Venus cept (VERO) - 2021 Q3 - Quarterly Report
2021-11-12 12:21
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-38238 Venus Concept Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 06-1681204 ...
Venus cept (VERO) - 2021 Q2 - Earnings Call Transcript
2021-08-13 18:32
Venus Concept Inc. (NASDAQ:VERO) Q2 2021 Earnings Conference Call August 13, 2021 8:00 AM ET Company Participants Dom Serafino - Chief Executive Officer Domenic Della Penna - Chief Financial Officer Chad Zaring - Chief Commercial Officer Conference Call Participants Marie Thibault - BTIG Jeffrey Cohen - Ladenburg Thalmann Jon Block - Stifel Suraj Kalia - Oppenheimer Anthony Vendetti - Maxim Group Operator Good morning, ladies and gentlemen and welcome to the Second Quarter 2021 Earnings Conference Call for ...
Venus cept (VERO) - 2021 Q2 - Quarterly Report
2021-08-13 11:25
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-38238 Venus Concept Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdic ...
Venus cept (VERO) - 2021 Q1 - Earnings Call Transcript
2021-05-18 06:05
Start Time: 17:00 January 1, 0000 5:57 PM ET Venus Concept Inc. (NASDAQ:VERO) Q1 2021 Earnings Conference Call May 17, 2021, 17:00 PM ET Company Participants Domenic Serafino - CEO Domenic Della Penna - CFO Chad Zaring - Chief Commercial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Suraj Kalia - Oppenheimer Jonathan Block - Stifel Marie Thibault - BTIG Anthony Vendetti - Maxim Group Operator Good afternoon, ladies and gentlemen, and welcome to the First Quarter 2021 Earnings Confe ...
Venus cept (VERO) - 2021 Q1 - Quarterly Report
2021-05-17 20:24
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-38238 Venus Concept Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdi ...
Venus cept (VERO) - 2020 Q4 - Earnings Call Transcript
2021-03-30 02:56
Venus Concept Inc. (NASDAQ:VERO) Q4 2020 Earnings Conference Call March 29, 2021 5:00 PM ET Company Participants Domenic Serafino - CEO Domenic Della Penna - CFO Chad Zaring - CMO Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Suraj Kalia - Oppenheimer Jonathan Block - Stifel Anthony Vendetti - Maxim Group Operator Good afternoon, ladies and gentlemen, and welcome to the Fourth Quarter of 2020 Earnings Conference Call for Venus Concept, Inc. At this time, all participants have been placed i ...
Venus cept (VERO) - 2020 Q4 - Annual Report
2021-03-29 20:35
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38238 Venus Concept Inc. (Exact name of Registrant as specified in its Charter) Delaware 06-1681204 (State or other jurisdiction of i ...
Venus cept (VERO) - 2020 Q3 - Earnings Call Transcript
2020-11-16 15:55
Financial Data and Key Metrics Changes - The company reported GAAP revenue of $20.7 million for Q3 2020, a decrease of 21% year-over-year, impacted by COVID-19 disruptions [8][41] - Sales increased by 22% on a quarter-over-quarter basis, indicating improving business trends [9] - Gross profit for Q3 2020 decreased by 28% year-over-year to $13.5 million, with a gross margin of 65.3% compared to 71.8% last year [49][50] - GAAP net loss for Q3 2020 was $7.3 million or $0.18 per share, compared to a net loss of $9 million or $1.77 per share in the prior year [59] Business Line Data and Key Metrics Changes - Sales of ARTAS and ARTAS iX systems increased by 46% year-over-year to $4.8 million, reflecting the success of the new commercial strategy [30][43] - Total products and services revenue increased by 16% year-over-year to $11.2 million, while lease revenue decreased by 43% year-over-year to $9.4 million [41] - The company saw a 33% increase in international sales quarter-over-quarter, driven by recovery in hair restoration procedures [19] Market Data and Key Metrics Changes - Approximately 90% of the global customer base was active with devices by September, compared to less than 10% in April [14] - In North America, procedures for ARTAS and ARTAS iX systems increased by 35% year-over-year, while international markets saw a 23% decline [16] - The EMEA region showed slower recovery in procedure trends, but there was an uptick in September compared to August [13] Company Strategy and Development Direction - The company is focused on enhancing competitive positioning and maximizing capital through a restructuring program aimed at reducing operating expenses by at least $20 million [31][32] - A targeted commercial strategy has been implemented to optimize the sales process and improve system adoption, particularly in the U.S. market [24][27] - The company is developing next-generation robotic technologies for medical aesthetic applications, aiming to improve safety and clinical predictability [35][36] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about improving business trends despite ongoing challenges from COVID-19, noting a recovery in procedure volumes [9][75] - The company plans to return to providing annual guidance for fiscal year 2021 during the fourth quarter call [66] - Management highlighted the importance of adapting to the evolving market and the commoditization of procedures, particularly in the injectables space [90] Other Important Information - The company has made significant progress in collections, achieving 104%, 97%, and 98% of expected collections in July, August, and September respectively [112] - The restructuring program has already realized over $7 million in cost savings during Q3 2020 [55] - The company plans to host a virtual R&D event on December 10 to discuss advancements in robotic technologies [37] Q&A Session Summary Question: Procedure volume recovery in the U.S. and EMEA - Management confirmed that procedure volume has returned to pre-COVID levels and is continuing to improve in October and November, with a positive trend in EMEA as well [75][76] Question: Details on the upcoming virtual event regarding robotics - The event will cover improvements in the implantation feature of the device and advancements in robotics beyond hair restoration [80][82] Question: Status of ARTAS and sustainability of recent performance - Management indicated that the new pricing model and improved cost of goods sold have contributed to the recent success of ARTAS, with a focus on sustainable growth [99][102] Question: Market acceptance of Venus Bliss - Management reported strong market acceptance and attractive payback periods for the Bliss system, appealing to both new and existing customers [109] Question: Update on international market performance - Management noted strong performance in European countries such as France, Germany, and Spain, while also discussing the strategy to close underperforming markets [126]
Venus cept (VERO) - 2020 Q3 - Quarterly Report
2020-11-16 12:52
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 Commission File Number: 001-38238 Venus Concept Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 06-1681204 (State or other jurisdiction of incorporation or organization) 235 Yorkland Blvd., Suite 900 Toronto, Ontario M2J 4Y8 (877) 848-8430 (Address including z ...
Venus cept (VERO) - 2020 Q2 - Earnings Call Transcript
2020-08-14 03:38
Venus Concept, Inc. (NASDAQ:VERO) Q2 2020 Earnings Conference Call August 13, 2020 5:00 PM ET Company Participants Domenic Serafino - CEO & Director Domenic Della Penna - CFO Chad Zaring - Chief Commercial Officer Conference Call Participants Suraj Kalia - Oppenheimer Anthony Vendetti - Maxim Group Marie Thibault - BTIG Operator Good afternoon, ladies and gentlemen, to the Second Quarter of 2020 Earnings Conference Call for Venus Concept. [Operator Instructions]. Please note that this conference call is bei ...